Eledon Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Eledon Pharmaceuticals has a total shareholder equity of $76.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $114.6M and $38.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$78.19m |
| Equity | US$76.06m |
| Total liabilities | US$38.52m |
| Total assets | US$114.58m |
Recent financial health updates
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Mar 22
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Dec 05Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Aug 10We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Apr 27Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation
Jan 05Recent updates
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart
Oct 29We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Mar 22Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Dec 05Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Aug 10We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Apr 27Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation
Jan 05Eledon adds 10% as FDA clears clinical trial for kidney disease candidate
Sep 06Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?
Aug 31Eledon gets FDA nod to start trial of organ rejection preventing therapy
Aug 01Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients
Jul 18Eledon gives update on development strategy for AT-1501 in renal transplantation
Apr 26Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans
Apr 14What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?
Feb 21Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation
Dec 30
Novus Therapeutics (NVUS) Investor Presentation - Slideshow
Dec 18Novus Therapeutics EPS misses by $3.76
Nov 16Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease
Nov 02Financial Position Analysis
Short Term Liabilities: ELDN's short term assets ($81.5M) exceed its short term liabilities ($12.5M).
Long Term Liabilities: ELDN's short term assets ($81.5M) exceed its long term liabilities ($26.0M).
Debt to Equity History and Analysis
Debt Level: ELDN is debt free.
Reducing Debt: ELDN had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ELDN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ELDN is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.